霍德義 教授

Teh-Ia Huo Professor

 

Professor

霍德義 教授 

Address: Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, 201, Sec. 2, Shih-Pai Rd, Taipei, Taiwan

 

E-mail: tihuo@vghtpe.gov.tw

 

 


 

Currently in office:

Professor, Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan

Attending physician, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

 

Membership in Medical Societies:

Member, Chinese Medical Association, Republic of China

Member, Taipei Physician's Association, Republic of China

Member, The Digestive Endoscopy Society of the Republic of China

Member, The Society of Internal Medicine, Republic of China

Member, Gastroenterological Society of Taiwan

Member, Taiwan Association for the Study of the Liver

 

Deputy Editor:

Journal of the Chinese Medical Association

 

Editorial Board:

Journal of Gastroenterology and Hepatology

 


Publications:

(* indicates corresponding author)

* corresponding author

Refereed paper included in Science Citation Index:

1.        Teh-IaHuo, Jaw-Ching Wu*, Chung-Ru Lai, Ching-Liang Lu, Wen-Yung Sheng, Shou-Dong Lee. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. J Hepatol 1996;25:439-44.

2.        Teh-IaHuo, Jaw-Ching Wu*, Wen-Yung Sheng, Cho-Yu Chan, Shinn-Jang Hwang, Trong-Zong Chen, Shou-Dong Lee. Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B. J Gastroenterol Hepatol 1996;11:560-5. (cited by the Oxford Textbook of Clinical Hepatology; Zakim & Boyer eds: “Hepatology: a Textbook of Liver Disease”)

3.        Teh-IaHuo, Jaw-Ching Wu*, Chang-Fang Chiu, Shou-Dong Lee. Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency. Am J Gastroenterol 1996;91:158-9. (cited by Zakim & Boyer eds: “Hepatology: a Textbook of Liver Disease”)

4.        Teh-IaHuo, Jaw-Ching Wu*, Fu-Shuen Yen, I-Jane Sheen, Shou-Dong Lee. Polymerase chain reaction analysis for viral nucleic acids in acute sporadic hepatitis patients negative for hepatitis B surface antigen and antibodies to hepatitis C virus. J Chin Med Asso 1996; 58:379-84.

5.        Teh-IaHuo, Jaw-Ching Wu*,Yi-Shin Huang, Chun-Ru Lai, Shi-How Tsay, Shou-Dong Lee. Autoimmune hepatitis in an area endemic for hepatitis B virus infection- a report of three cases. J Chin Med Asso 1996;57:360-4.

6.        Teh-IaHuo, Jaw-Ching Wu*, Ruey-Yi Lin, Wen-Yung Sheng, Full-Young Chang, Shou-Dong Lee. Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors. J Gastroenterol Hepatol 1997;12:747-51. (with an editorial)

7.        Teh-IaHuo, Jaw-Ching Wu*, Pui-Ching Lee, Gar-Yang Chau, Wing-Yiu Lui, Shyh-Haw Tsay, Ling-Tan Ting, Full-Young Chang, Shou-Dong Lee. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231-6. (with an editorial)

8.        Teh-IaHuo, Jaw-Ching Wu*, Yi-Hsiang Huang, Ueng-Cheng Yang, I-Jane Sheen, Full-Young Chang, Shou-Dong Lee. Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome. J Gastroenterol Hepatol 1998;13:1138-42.

9.        Teh-Ia Huo, Jaw-Ching Wu*, Pui-Ching Lee, Shyh-Haw Tsay, Full-Young Chang, Shou-Dong Lee. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol 2000;30:250-4. (with an editorial)

10.    Teh-Ia Huo*, Jaw-Ching Wu, Shinn-Jang Hwang,Chung-Ru Lai, Pui-ChingLee,Shyh-Haw Tsay,Full-Young Chang, Shou-Dong Lee. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 2000;12:687-93.

11.    Teh-Ia Huo*,Wu-Chang Yang,Jaw-Ching Wu, Kuang-Liang King, Che-Chuan Loong, Wui-Yaw Lui,Full-Young Chang, Shou-Dong Lee. Impact of hepatitis B and C virus infection on the outcome of kidney transplantation in Chinese patients. J Chin Med Asso 2000;63:93-100.

12.    Teh-IaHuo*, Wu-Chang Yang,Jaw-Ching Wu,Kuang-Liang King, Ching-Yuang Lin,Che-Chuan Loong, Wing-Yiu Lui, Full-Young Chang, Shou-Dong Lee. Long-term outcome of kidney transplantation in patients with hepatitis C virus infection. Hepato-Gastroenterology 2001;48:169-73.

13.    Teh-IaHuo*, Wu-Chang Yang, Jaw-Ching Wu, Kuang-Liang King, Che-Chuan Loong, Ching-Yuang Lin, Full-Young Chang, Shou-Dong Lee. Kidney transplantation in patients with chronic hepatitis B virus infection: is the prognosis worse? Dig Dis Sci 2001;46:469-75.

14.    Teh-IaHuo, Xin Wang, Marshonna Forgues, Chuan-Ging Wu, Elisa Spillare, Carlo Giannini, Christian Brechot, Curtis Harris*.Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 2001;20:3620-8.

15.    Teh-IaHuo*, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. Scand J Gastroenterol 2002;37:350-5.

16.    Teh-IaHuo*, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 2003;38:770-8.

17.    Teh-IaHuo, Jaw-Ching Wu*, Shou-Dong Lee. Outcomes of patients with seroclearance of HBsAg: different facets of a truth. Gastroenterology 2003;125:274-5.

18.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Screening for hepatocellular carcinoma in high-risk patients: western versus eastern virus. Hepatology 2003;38: 269.

19.    Teh-IaHuo*, Wing-Yiu Lui,Yi-Hsiang Huang,Gar-Yang Chau,Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang,Shou-Dong Lee. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003;98:2293-8.

20.    Teh-IaHuo*, Jaw-Ching Wu, Wing-Yiu Lui,Pui-Ching Lee, Yi-Hsiang Huang,Gar-Yang Chau,Shyh-Haw Tsay, Full-Young Chang,Shou-Dong Lee.Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur J Gastroenterol Hepatol 2003;15:1203-8.

21.    Teh-IaHuo*, Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang,Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. Ann Oncol 2003;14:1648-53.

22.    Teh-IaHuo, Jaw-Ching Wu*, Shiow-Ing Wu, An-Lung Chang, Shih-Ku Lin, Chun-Hung Pan, Yi-Hsiang Huang, Full-Young Chang, Shou-Dong Lee. Changing seroepidemiology of hepatitis B, C and D virus infections in high-risk populations. J Med Virol 2004;72:41-5.(Zakim & Boyer eds: “Hepatology: aTextbook of Liver Disease” 2006)

23.    Teh-IaHuo*, Jaw-Ching Wu,Wing-Yiu Lui,Rheun-ChuanLee,Che-Chuan Loong,Yi-Hsiang Huang,Shyh-Haw Tsay,Full-Young Chang, Shou-Dong Lee. Reliability of the contemporary radiology to measure tumor size of hepatocellular carcinoma in patients undergoing resection: limitations and clinical implications. Scand J Gastroenterol 2004;39:46-52.

24.    Teh-IaHuo*, Jaw-Ching Wu, Yi-Hsiang Huang, Wing-Yu Lui,Jen-Huei Chiang, Pui-Ching Lee, Shyh-Haw Tsay, Full-Young Chang, Shou-Dong Lee. Selective prognostic impact of serum a-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004;11:543-50.

25.    Teh-IaHuo*, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. Eur J Gastroenterol Hepatol 2004;16:325-31.(VGH 93-225)

26.    Teh-IaHuo*, Jaw-Ching Wu, Wing-Yiu Lui, Yi-Hsiang Huang, Pui-Ching Lee, Jen-Huei Chiang, Full-Young Chang, Shou-Dong Lee. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and non-surgical treatment. Am J Gastroenterol 2004;99:1479-87. (with an editorial)(VGH 93-225)

27.    Teh-IaHuo*, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Persistent retention of acetic acid is associated with complete tumor necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection. Scand J Gastroenterol 2004;39:168-73.

28.    Teh-IaHuo*, Wing-Yiu Lui, Jaw-Ching Wu, Yi-Hsiang Huang, Kuang-Liang King, Che-Chuan Loong, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors and association with intrahepatic tumor recurrence. World J Surg 2004;28:258-62. (VGH 93-225)

29.    Teh-IaHuo*, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004;24:210-5. (VGH 93-225)

30.    Teh-IaHuo, Jaw-Ching Wu*. Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B? J Gastroenterol Hepatol 2004;19:841-3.

31.    Teh-IaHuo*, Jaw-Ching Wu, Cheng-Yuan Hsia, Gar-Yang Chau, Wing-Yiu Lui, Yi-Hsiang Huang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Hepatitis C virus infection is a risk factor of tumor recurrence after resection for small hepatocellular carcinoma. World J Surg 2004;28:787-91. (VGH 93-225)

32.    Teh-IaHuo*, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. Ann Oncol 2004;15:775-80. (VGH 93-225)

33.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Staging for hepatocellular carcinoma: look for a perfect classification system. J Hepatol 2004;40:1041-2.

34.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Is diabetes a risk factor for hepatocellular carcinoma? Gastroenterology 2004;127:360-1.

35.    Teh-IaHuo*,Jaw-Ching Wu, Yi-Hsiang Huang,Jen-Huei Chiang, Pui-Ching Lee,Full-Young Chang,Shou-Dong Lee. Acute renal failure after transarterial chemoemboilzation for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther 2004;19:999-1007.(VGH 93-225)

36.    Teh-IaHuo*, Jaw-Ching Wu, Shou-Dong Lee. Long-term outcome of hepatitis C virus superinfection in HBsAg carriers. Gastroenterology 2004;127;690.

37.    Teh-IaHuo*,Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang, Pui-Ching Lee,Full-Young Chang,Shou-Dong Lee. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as theprimary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. Aliment Pharmacol Ther 2004;19:1391-8. (VGH 93-225)

38.    Teh-IaHuo*, Jaw-Ching Wu, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Yi-Hsiang Huang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transplant2004;10:1507-13.(NSC 93-2314-B-010-043)

39.    Teh-IaHuo*, Jaw-Ching Wu, Sou-Dong Lee. Contrast medium-associated renal dysfunction in patients with cirrhosis. Hepatology 2004;40:1474.

40.    Teh-IaHuo*, Shou-Dong Lee. Management of inoperable hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:S272-S278.

41.    Teh-IaHuo*, Jaw-Ching Wu, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Evaluation of the increase in model for end-stage liver disease (DMELD) score over time as a prognostic predictor in patients with advanced liver cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42: 826-32.(with an editorial)(NSC 93-2314-B-010-043)

42.    Teh-IaHuo*, Yi-Hsiang Huang. Staging for hepatocellular carcinoma: treatment strategy matters. Hepatology 2005;41:678.

43.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Ethanol injection versus radiofrequency ablation for hepatocellular carcinoma: which is better? Gastroenterology 2005;128:806-7.

44.    Teh-IaHuo*, Jaw-Ching Wu, Shou-Dong Lee. MELD in liver transplantation: the da Vinci code for the Holy Grail? J Hepatol 2005;42:474-5.

45.    Teh-IaHuo*, Jaw-Ching Wu, Shou-Dong Lee. Arealcohol, tobacco and obesity genuine risk factors for hepatocellular carcinoma? J Hepatol 2005;42:941.

46.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Which is the holy grail in liver transplantation, hyponatremia, MELD or combination? Liver Transplant 2005;11:710.

47.    Teh-IaHuo*, Yi-HsiangHuang, Shou-Dong Lee, Jaw-Ching Wu. Is there an ideal prognostic model for hepatocellular carcinoma? Gut 2005;54:1348.

48.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Risk factor analysis for cholangiocarcinoma: limitations of cross-sectional study. Gastroenterology 2005;129:395.

49.    Teh-IaHuo*, Jaw-Ching Wu, Shou-Dong Lee. Comparison of staging systems for HCC: one more positive answer or mission impossible? Hepatology 2005;42:238-9.

50.    Teh-IaHuo*, Han-Chieh Lin, Shou-Dong Lee. Liver transplantation is a time dependent prognostic predictor in cirrhotic patients with esophageal varices. Gastroenterology 2005;129:769-70.

51.    Teh-IaHuo*, Jaw-Ching Wu, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Different model for end-stage liver disease score block distributions may have a variable ability for outcome prediction in cirrhotic patients. Transplantation 2005;80:1414-8. (VGH 94-224)

52.    Teh-IaHuo*, Yi-Hsiang Huang, Jaw-Ching Wu. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and look into future. J Chin Med Asso2005;68:155-9.

53.    Teh-IaHuo*, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Jaw-Ching Wu, Full-Young Chang, Shou-Dong Lee. Occurrence of cirrhosis-related complications is a time dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int 2006;26:55-61. (VGH V95C1-009)

54.    Teh-IaHuo*, Han-Chieh Lin, Jaw-Ching Wu, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee.Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transplant2006;12:65-71. (Szu-Yuan Research Foundation of Internal Medicine)

55.    Teh-IaHuo*, Ming-Chih Hou, Han-Chieh Lin, Jaw-Ching Wu, Fa-Yauh Lee, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. Clin Transplant2006;20:188-94. (NSC 94-2314-B-010-049)

56.    Teh-IaHuo*, Yi-Hsiang Huang, Han-Chieh Lin, Jaw-Ching Wu, Jen-Huei Chiang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee.Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoingloco-regional therapy. Am J Gastroenterol 2006;101:975-82.(DOH-093030148)

57.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu.Do baseline ALT levels predict complications of chronic hepatitis B? Gut 2006;55:745.

58.    Teh-IaHuo*, Han-Chieh Lin, Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang, Pui-Ching Lee, Shou-Dong Lee.The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoingloco-regional therapy. Cancer 2006;107:141-8.(NSC 94-2314-B-010-049)

59.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Hepatitis after arterial embolization for hepatocellular carcinoma: viral reactivation or ischemia?Hepatology 2006:43:1400-1.

60.    Teh-IaHuo*, Pui-Ching Lee,Yi-Hsiang Huang, Jaw-Ching Wu, Han-Chieh Lin, Jen-Huei Chiang, Full-Young Chang, Shou-Dong Lee.The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing loco-regional therapy. J Clin Gastroenterol 2006;40:543-50.(NSC 94-2314-B-010-049)

61.    Teh-IaHuo*, Yi-Hsiang Huang, Hui-Chun Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee.Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: incidence and risk factor analysis. J Clin Gastroenterol 2006:60:639-42. (DOH-093030148)

62.    Teh-IaHuo*, Shou-Dong Lee, Jaw-Ching Wu. Role of loco-regional therapy forhepatocellular carcinoma before liver transplantation: answer or myth? Liver Transplant 2006;12:1560.

63.    Teh-IaHuo*, Shou-DongLee. Role of the model for end-stage liver disease and serum a-fetoprotein as prognostic predictors for hepatocellular carcinoma. Liver Int 2006;26:1300-1.

64.    Teh-IaHuo*, Han-Chieh Lin, Shou-DongLee. Model for end-stage liver disease and organ allocation in liver transplantation: where are we and where should we go?J Chin Med Asso2006;69:193-8.

65.    Cheng-Yuan Hsia, Teh-IaHuo*,Shu-Yuan Chiang, Ming-Fong Lu,Chia-Lu Sun, Jaw-Ching Wu, Pui-Ching Lee, Chin-Wen Chi, Wing-Yiu Lu, Shou-Dong Lee. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007;33:208-12.

66.    Teh-IaHuo*, Yi-Hsiang Huang, Jen-Huei Chiang, Jaw-Ching Wu, Pui-Ching Lee, Chin-Wen Chi, Shou-DongLee. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing loco-regional therapy:Is there alead-time bias? Scand J Gastroenterol 2007;42:485-92. (VGH 94-224)

67.    Teh-IaHuo, Ying-Wen Wang, Ying-Ying Yang, Han-Chieh Lin*, Pui-Ching Lee, Ming-Chih Hou,Fa-Yauh Lee, Shou-Dong Lee. The model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int 2007;27:498-506. (NSC 95-2314-B-010-014) (with an editorial)

68.    Teh-IaHuo*, Cheng-Yuan Hsia,Chi-Jen Chu, Yi-Hsiang Huang, Wing-Yiu Lui, Jaw-Ching Wu, Pui-Ching Lee, Chin-Wen Chi, Shou-DongLee.The predictive ability of serum a-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. J Surg Oncol 2007;95:645-51.(Szu-Yuan Research Foundation of Internal Medicine)

69.    Ying-WenWang, Teh-IaHuo (equal contribution), Ying-Ying Yang,Ming-Chih Hou,Pui-Ching Lee, Han-Chieh Lin*, Fa-Yauh Lee, Chin-Wen Chi, Shou-Dong-Lee. Correlation andcomparison of the model for end-stage liver disease, portal pressure and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol 2007;41:706-12.(VGH V95C1-009)(with an editorial)

70.    Teh-IaHuo*, Han-Chieh Lin, Cheng-Yuan Hsia,Pui-Ching Lee, Jaw-Ching Wu, Chin-Wen Chi, Shou-Dong Lee. The model for end-stage liver disease basedcancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 2007;102:1920-30. (NSC 95-2314-B-010-014).

71.    Teh-IaHuo*, Jaw-Ching Wu, Shou-Dong Lee.Does hepatitis B viral load determine the outcome of patients with hepatocellular carcinoma undergoing chemotherapy? Hepatology 2007;46:1665-6.

72.    Teh-IaHuo*, Han-Chieh Lin, Shou-Dong Lee. To MELD or not to MELD, that is a question.Liver Transpl2007;13:1618.

73.    Samantha Huo,Teh-IaHuo*, Han-Chieh Lin, Chin-Wen Chi, Pui-Ching Lee, Fan-Wei Tseng, Shou-Dong Lee. Is the corrected-creatinine MELD a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation 2007;84:1406-12.(NSC 95-2314-B-010-014,VGH V96C1-003).

74.    Teh-IaHuo,Shou-Dong Lee, Han-Chieh Lin*. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008;28: 606-13. (VGH V97C1-001, NSC96-2314-B-010-023-MY2).

75.    Teh-IaHuo*,Han-Chieh Lin, Samantha C. Huo, Pui-Ching Lee, Jaw-Ching Wu, Fa-Yauh Lee, Ming-Chih Hou, Shou-Dong Lee. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl 2008; 14: 837-44.(NSC 96-2314-B-010-023-MY2, VGH V95C1-009).

76.    Teh-IaHuo*, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin,Jen-Huei Chiang, Yi-You Chiou, Samantha C. Huo,Pui-Ching Lee, Shou-Dong Lee. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma (HCC) undergoing locoregional therapy. Clin Transplant 2008;22:469-75.(V96C1-003 and NSC96-2314-B-010-023-MY2).

77.    Teh-IaHuo, Han-Chieh Lin*. Metastatic hepatocelliular carcinoma: when, how, where and so what? Liver Int 2008;28:1183-5.

78.    Teh-IaHuo*,Han-Chieh Lin, Cheng-Yuan Hsia, Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang,Yi-You Chiou, Wing-Yiu Lui, Pui-Ching Lee, Shou-Dong Lee. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: aprospective survey. Dig Liver Dis 2008;40:882-9. (VGH V95C1-009, NSC 96-2314-B-010-023-MY2).

79.    Teh-IaHuo*, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su,Han-Chieh Lin, Chia-Yang Hsu, Pui-Ching Lee, Wing-Yiu Lui,Che-Chuan Loong, Jen-Huei Chiang, Yi-You Chiou, Shou-Dong Lee. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? Liver Int 2009;29:767-73.(NSC 95-2314-B-010-014, VGH V95C1-009)

80.    Teh-IaHuo*, Cheng-Yuan Hsia, Yi-Hsiang Huang, Han-Chieh Lin, Pui-Ching Lee, Wing-Yiu Lui, Jen-Huei Chiang, Yi-You Chiou, Che-Chuan Loong, Shou-Dong Lee.Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium and five cancer staging systems. J Clin Gastroenterol 2009;43:773-81.(with an editorial)(NSC 96-2314-B-010-023-MY2, VGH V95C1-009).

81.    Hui-Chun Huang, Fa-Yauh Lee, Teh-IaHuo*. Complications of cirrhosis: major adverse events, pre-transplant assessment and outcome prediction. J Gastroenterol Hepatol 2009;24:1716-24.

82.    Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin,Jen-Huey Chiang, Pui-Ching Lee, Fa-Yauh Lee, Teh-IaHuo*,Shou-Dong Lee. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 2010;30:77-84. (with an editorial)(NSC 96-2314-B-010-023-MY2, VGH V98C1-132).

83.    Teh-IaHuo*, Chia-Yang Hsu,Yi-Hsiang Huang, Cheng-Yuan Hsia, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huey Chiang, Yi-You Chiou, Shou-Dong Lee.Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010; 30: 198-207. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)

84.    Chia-Yang Hsu, Han-Chieh Lin, Yi-Hsiang Huang, Chien-Wei Su,Fa-Yauh Lee, Teh-IaHuo*, Pui-Ching Lee, Jing-Yi Lee,Shou-Dong Lee. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis 2010;42:137-42. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)

85.    Teh-IaHuo*, Chia-Yang Hsu, Han-Chieh Lin, Pui-Ching Lee,Jing-Yi Lee, Fa-Yauh Lee, Ming-Chih Hou, Shou-Dong Lee. Selecting an optimal cutoff value for creatinine in the model for end-stage liver disease equation. Clin Transplant 2010;24:157-63. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)

86.    Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huei Chiang, Teh-IaHuo*, Shou-Dong Lee. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010;116:3006-14. (NSC96-2314-B-010-023-MY2, VGH V98C1-132)

87.    Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su,Han-Chieh Lin, Che-Chuan Loong, Yi-You Chiou, Jen-Huey Chiang,Pui-Ching Lee, Teh-IaHuo*,Shou-Dong Lee. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring system. J Hepatol 2010;53:108-17.(with an editorial)

88.    Chia-Yang Hsu, Yi-Hsiang Huang, Jen-Huey Chiang, Han-Chieh Lin, Chien-Wei Su, Pui-Ching Lee, Fa-Yauh Lee, Teh-IaHuo*, Shou-Dong Lee. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J Clin Gastroenterol 2010; 44: e171-e177. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)

89.    Teh-IaHuo*,Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Jen-Huey Chiang, Pui-Ching Lee, Shou-Dong Lee. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010;10:146.

90.    Teh-IaHuo*. The global spread of 2009 H1N1 influenza: afalse pandemic? J Chin Med Assoc2010;73:60-1.

91.    Teh-IaHuo*. The first case of multidrug-resistantNDM-1-harboring Enterobacteriaceae in Taiwan: Here comes the superbacteria! J Chin Med Assoc2010;73:557-8.

92.    Lee IC, Chan CC, HuangYH*,HuoTI*,Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Comparative analysis of noninvasive models to predict early liver fibrosis in hepatitis B e antigen-negative chronic hepatitis B. J Clin Gastroenterol 2011;45:278-85.

93.    Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin,Yi-You Chiou, Rheun-Chuan Lee, Jen-Huey Chiang,Teh-IaHuo*, Fa-Yauh Lee, Shou-Dong Lee. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria:a propensity score analysis. Liver Transpl 2011;17:556-66.

94.    I-Fang Hsin, Chia-Yang Hsu, Hui-Chun Huang, Yi-Hsiang Huang, Han-Chieh Lin, Rheun-Chuan Lee, Jen-Huey Chiang, Fa-Yauh Lee, Teh-IaHuo*, Shou-Dong Lee.Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors and prognostic prediction. J Clin Gastroenterol 2011;45:556-62.

95.    Hsin-Yang Li, Yueh Chien, Yi-Jen Chen, Szu-Fu Chen, Yuh-Lih Chang, Chih-Hung Chiang,Shaw-Yeu Jeng, Chia-Ming Chang, Mong-Lien Wang, Liang-Kung Chen, Shuen-Iu Hung,Teh-IaHuo*, Shou-Dong Lee, Shih-HwaChiou*. Reprogramming induced pluripotent stem cells in the absence of c-Myc fordifferentiation into hepatocyte-like cells. Biomaterials 2011;32:5994-6005.

96.    Ya-Ju Tsai, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Jen-Huey Chiang,Teh-IaHuo*, Shou-Dong Lee. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975-84.

97.    Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Jih-Tung Pai, Che-Chuan Loong, Yi-You Chiou, Rheun-Chuan Lee, Fa-Yauh Lee, Teh-IaHuo*, Shou-Dong Lee. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milancriteria: apropensity score analysis. Ann Surg Oncol 2012;19:842-9.

98.    Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Yi-You Chiou, Rheun-Chuan Lee, Fa-Yauh Lee,Teh-IaHuo*, Shou-Dong Lee. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy. J Gastroenterol Hepatol 2012;27:690-9.

99.    Hua-Ming Chang, Yi-Wen Liao, Chih-Hung Chiang, Yi-Jen Chen, Ying-Hsiu Lai, Yuh-Lih Chang, Hen-Li Chen, Shaw-Yeu Jeng, Jung-Hung Hsieh, Chi-Hsien Peng, Hsin-Yang Li, Yueh Chien*, Szu-Yu Chen,Liang-Kung Chen,Teh-IaHuo*. Improvement of carbon tetrachloride-induced acute hepatic failure bytransplantation of induced pluripotent stem cellswithout reprogramming factor c-Myc. Int J Mol Sci 2012;13:3598-617.

100.             Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang,Chien-Wei Su,Han-Chieh Lin, Yi-You Chiou,Teh-IaHuo*. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther 2012;36:551-9.

101.             Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su,Han-Chieh Lin, Che-Chuan Loong,Yi-You Chiou,Teh-IaHuo*. Defining the severity ofliver dysfunction in patients with hepatocellular carcinomaby the model for end-stage liver disease-derived systems. Dig Liver Dis 2012;44:868-74.

102.             Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su,Han-Chieh Lin, Rheun-Chuan Lee,Yi-You Chiou,Teh-IaHuo*, Shou-Dong Lee. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol 2012;27:1581-8.

103.             Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia,Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Fa-Yauh Lee,Teh-IaHuo*. Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancersystem. Hepatology 2013;57:112-9.

104.             Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang,Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Teh-IaHuo*. Hepatocellular carcinoma in uremic patients: Is there evidence for an increased risk of mortality? J Gastroenterol Hepatol 2013;28:348-56.

105.             Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Cheng-Yuan Hsia,Teh-IaHuo*. a-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma. J Gastrointest Surg 2013;17:730-8.

106.             Chia-Yang Hsu, Yun-Hsuan Lee, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Fa-Yauh Lee,Teh-IaHuo*, Shou-Dong Lee. Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact and staging strategy. Hepatol Int 2013;7:188-98.

107.             Yun-Hsuan Lee, Cheng-Yuan Hsia, Chia-Yang Hsu, Yi-Hsiang Huang, Han-Chieh Lin, Teh-IaHuo*. Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. World J Surg 2013;37:1348-55.

108.             Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Yi-You Chiou, Fa-Yauh Lee, Teh-IaHuo*. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the Milancriteria. Ann Surg Oncol 2013;20:2035-42.

109.             Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia,Yi-Hsiang Huang, Chien-Wei Su,Yi-You Chiou,Han-Chieh Lin, Teh-IaHuo*, Shou-DongLee. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 2013;7:645-54.

110.             Yun-Hsuan Lee, Chia-Yang Hsu,Teh-IaHuo*. Assessing liver dysfunction in cirrhosis: Role of the model for end-stage liver disease and its derived systems. J Chin Med Asso 2013;76:419-24.

111.             Chia-Yang Hsu, Yun-Hsuan Lee, Po-Hong Liu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Han-Chieh Lin, Yi-You Chiou, Fa-Yauh Lee, Teh-IaHuo*. Decrypting cryptogenic hepatocellular carcinoma: Clinical manifestations, prognostic factors and long-term survival by propensity score model. PLoS One 2014;9: e89373.

112.             Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Chia-Yang Hsu, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol 2014;21:1825-33.

113.             Yun-Hsuan Lee, Chia-Yang Hsu, Chen-Wei Chu, Po-Hong Liu, Cheng-Yuan Hsia, Yi-Hsiang Huang,Chien-Wei Su, Yi-You Chiou,Han-Chieh Lin, Teh-IaHuo*.A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. PLoS One 2014;9: e99115.

114.             Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Yi-You Chiou, Chien-Wei Su, Han-Chieh Lin, Teh-IaHuo*. Vascular invasion in hepatocellular carcinoma: Prevalence, determinants and prognostic impact. J Clin Gastroenterol 2014;48:734-41.

115.             Po-Hong Liu, Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, MD, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond the Milancriteria independent of performance status.J Gastrointest Surg 2014;18:1623-31.

116.             Po-Hong Liu, Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within Milancriteria. Ann Surg Oncol 2014;21:3835-43.

117.             Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: A propensity score analysis. Medicine 2014;93:e264.

118.             Chuan-Fu Chen, Po-Hong Liu, Yun-Hsuan Lee, Ya-Ju Tsai, Chia-Yang Hsu,Yi-Hsiang Huang, Yi-You Chiou, Teh-IaHuo*. Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. J Gastroenterol Hepatol 2015;30:192-8.

119.             Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Rheun-Chuan Lee, Han-Chieh Lin,Teh-IaHuo*. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J Surg Oncol 2015;111:404-9.

120.             Yun-Hsuan Lee, Chia-Yang Hsu,Chen-Wei Chu, Po-Hong Liu,Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou,Han-Chieh Lin, Teh-IaHuo*. Radiofrequency ablation is better than surgical resection in patients with small hepatocellular carcinoma and preserved liver function. J Clin Gastroenterol 2015;49:242-9.

121.             Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Yi-You Chiou, Ya-Ju Tsai, Teddy S. Nagaria, Teh-IaHuo*. Aggressive therapeutic strategies improve survival of hepatocellular carcinoma patients with performance status 1 or 2:A propensity score analysis. Ann Surg Oncol 2015;22:1324-31.

122.             Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. Hepatocellular carcinoma patients with performance status 1 deserve new classification and treatment algorithm in the BCLC system. Medicine 2015;94:e1223.

123.             Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia,Yi-Hsiang Huang, Han-Chieh Lin, Yi-You Chiou, Fa-Yauh Lee,Teh-IaHuo*. Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: What is the most optimal cutoff? PLoS ONE 2015;10:e0118825.

124.             Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Chien-Wei Su, Cheng-Yuan Hsia, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. Hong Kong Liver Cancer staging system is associated with better performance for hepatocellular carcinoma: Special emphasis on viral etiology. Medicine 2015;94:e1772.

125.             Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Ya-Ju Tsai, Teddy S. Nagaria, Han-Chieh Lin,Teh-IaHuo*. Active treatments prolong the survival in patients with hepatocellular carcinoma and performance status 3 or 4: A propensity score analysis. J Clin Gastroenterol 2015;49:878-884.

126.             Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. When to perform surgical resection or radiofrequency ablation for early hepatocellular carcinoma? A nomogram-guided treatment strategy. Medicine 2015;94:e1929.

127.             Po-Hong Liu,Teh-IaHuo*. Surgery for advanced hepatocellular carcinoma: Time to take action. J Surg Oncol 2015;112:909.

128.             Po-Hong Liu, Chia-Yang Hsu,Cheng-Yuan Hsia,Yun-Hsuan Lee, Chien-Wei Su, Yi-Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Teh-IaHuo*. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol 2016;64:601-608. (with an editorial)

129.             Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Teddy S. Nagaria, Rheun-Chuan Lee,Han-Chieh Lin, Teh-IaHuo*. Surgical resection is better than transarterial chemoembolization for patients with hepatocellular carcinoma beyond the Milan criteria: a prognostic nomogram study. Ann Surg Oncol 2016;23:994-1002.

130.             Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-IaHuo*. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. Ann Surg 2016;263:538-545.

131.             Po-Hong Liu,Teh-IaHuo*. Reply to “Hepatocellular carcinoma scoring and staging systems: Do we need new tools?” J Hepatol 2016;64:1450-1452.

132.             Po-Hong Liu, Chien-Wei Su, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Rheun-Chuan Lee, Han-Chieh Lin, Teh-IaHuo*. Solitary large hepatocellular carcinoma: Staging and treatment strategy. PLoS One 2016;11: e0155588.

133.             Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-Hsiang Huang, Chien-Wei Su, Fa-Yauh Lee, Han-Chieh Lin, Teh-IaHuo*. Proposal and validation of anew model to estimate survival for hepatocellular carcinoma patients. Eur J Cancer 2016;63:25-33.

134.             Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia,Yun-Hsuan Lee, Alhareth Al Juboori, Rheun-Chuan Lee,Han-Chieh Lin,Teh-IaHuo*. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver Int 2016;36:1498-1506.

135.             Chia-Yang Hsu, Teh-IaHuo*. Nomogram of the Barcelona Clinic Liver Cancer system: on the go. Liver Int 2016;36:1717-1718.

136.             Po-Hong Liu, Teh-IaHuo*.Utility of prognostic scoring systems in management of hepatocellular carcinoma. Eur J Cancer 2016;68:206-207.

137.             Yu-Wen Su, Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Shu-Yein Ho, Ming-Chih Hou, Harn-Shen Chen, Teh-IaHuo*. Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. PLoS One 2017;12:e0174333.

138.             Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-YouChiou, MD, Yi-Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Ming-Chih Hou,Teh-IaHuo*. ALBI and PALBI grade predict survival for hepatocellular carcinoma across treatment modalities and BCLC stages in the MELD era. J Gastroenterol Hepatol 2017;32:879-886.

139.             Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Rheun-Chuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Ya-Ju Tsai, Teh-IaHuo*. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One 2017;12:e0180408.

140.             Po-Hong Liu,Teh-IaHuo*. Treating very early-stage HCC: Have we found the Holy Grail? Ann Surg 2017;266:e31-e32.

141.             Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Teddy S. Nagaria, Rheun-Chuan Lee, Shu-Yein Ho, Ming-Chih Hou, Teh-IaHuo*. A new treatment-integrated prognostic nomogram of the Barcelona Clinic Liver Cancer system for hepatocellular carcinoma. Sci Rep 2017;7:7914.

142.             Teh-IaHuo*, Po-Hong Liu, Chia-Yang Hsu. ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: Is it sufficient? Liver Cancer 2017;6:375-376.

143.             Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Yi-Hsiang Huang, Yun-Hsuan Lee, Yi-You Chiou, Ting-Hui Hsieh, Tom Fang, Ya-Ju Tsai, Ming-Chih Hou, Teh-IaHuo*. Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS One 2017;12:e0188031.

144.             Teh-IaHuo*, Po-Hong Liu, Chia-Yang Hsu. Comment on 'Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function andvascular invasion'. Br J Cancer 2017;117:e5.

145.             Teh-IaHuo*, Chia-Yang Hsu, Po-Hong Liu. Performance status in patients with HCC: New kid on the block. J Hepatol 2017;67:1352-1353.

146.             Po-Hong Liu, Teh-IaHuo*. Ablation for hepatocellular carcinoma: Where do we stand? Ann Surg 2017;266:e55-e56.

147.             Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-You Chiou, Chien-Wei Su, Yun-Hsuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Teh-IaHuo*. Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation. Sci Rep 2018;8:843.

148.             Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Cheng-Yuan Hsia, Praneeth Kudaravalli, Yun-Hsuan Lee, Yi-You Chiou, Ya-Ju Tsai, Yi-Hsiang Huang, Teh-IaHuo*. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer2018;18:289.

149.             Teh-IaHuo*, Po-Hong Liu, Chia-Yang Hsu. Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea? J Hepatol 2018;68:862-863.

150.             Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Chien-Wei Su, Yun-Hsuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Teh-IaHuo*. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep 2018;8:4773.

151.             Teh-IaHuo*, Chia-Yang Hsu, Po-Hong Liu. Magic mirror on the wall:Which is the best biomarker for hepatocellular carcinoma? Hepatology 2018 (in press)

152.             Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Yi-Hsiang Huang, Yun-Hsuan Lee, Rheun-Chuan Lee, Teddy S. Nagaria, Ming-Chih Hou, Teh-IaHuo*. Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the BCLC system. Liver Int 2018 (in press)

153.             Jaw-Ching Wu*, Kong-Bung Choo, Chuan-Mu Chen, Trong-Zong Chen, Teh-IaHuo, Shou-Dong Lee. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995;346:939-41.

154.             Trong-Zong Chen, Jaw-Ching Wu*, Fu-Shun Yen, Wen-Yung Shen, Shinn-Jang Hwang, Teh-IaHuo, Shou-Dong Lee. Injection with non-disposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan. J Med Virol 1995;46:247-51.

155.             Yi-Hsiang Huang, Jaw-Ching Wu*, Wen-Yung Sheng, Teh-IaHuo, Full-Young Chang, Shou-Dong Lee. Diagnostic value of anti-HDV antibodies revisited: a study of total and IgM anti-HDV compared with detection of HDV RNA by polymerase chain reaction. J Gastroenterol Hepatol 1998;13:57-61.

156.             Jaw-Ching Wu*, Tzen-Yuh Chiang, Yi-Hsiang Huang, Teh-IaHuo, Shing-Jang Hwang, I-Shinn Huang, Wen-Yung Sheng, Shou-Dong Lee. Prevalence, implication and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and non-fulminant hepatitis. J Med Virol 1998;56:118-22.

157.             Han HF, Wu JC*,HuoTI, Kao KP, Huang YH, Chang FY, Lee SD. Chronic hepatitis B exacerbated by Guillain-Barre syndrome: a report of two cases. J Chin Med Asso 1999;62:652-6.

158.             Yi-Hsiang Huang, Jaw-Ching Wu*, Wing-Yiu Lui, Gar-Yang Chau, Shin-Haw Tsay, Jen-Huey Chiang, Kuang-Liang King, Teh-IaHuo, Full-Young Chang, Shou-Dong Lee. A prospective case controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. WorldJSurg 2000;24:551-5.

159.             Yi-Hsiang Huang, Jaw-Ching Wu*, Tzen-Yuh Chiang, Yu-Jiun Chan, Teh-IaHuo, Yi-Shin Huang, Shinn-Jang Hwang, Full-Young Chang, Shou-Dong Lee. Detection and viral nucleotide sequence analysis of TT virus infection in acute fulminant and non-fulminant hepatitis. J Viral Hepati 2000;7:56-63.

160.             Lin CC, Wu JC*, Chang SC, Huang YH, HuoTI, Chang FY, Lee SD. Resolution of refractory hepatic hydrothorax after chemical pleurodesis with minocycline. J Chin Med Asso 2000;63:704-9.

161.             Lin CC, Wu JC*, Huang DF, Huang YS, Huang YH, HuoTI, Chang FY, Lee SD.Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases.J GastroenterolHepatol 2001;16:481-3.

162.             Su CW, Wu JC*, Huang YS, HuoTI, Huang YH, Lin CC, Chang FY, Lee SD. Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. J Gastroenterol Hepatol 2002;17:1187-91.

163.             Wang XW*, Hussain SP, HuoTI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002;181-182:43-7.

164.             Huang HC, Huang YS, Wu JC*, Tsay SH, HuoTI, Wang YJ, Lo JC, Chen CY, Li CP, Chang FY, Lee SD. Characteristics of autoimmune hepatitis in Taiwan: the 11 years' experiences of a medical center.J Chin Med Asso2002;65:563-9.

165.             Huang YH, Wu JC*, Chang TT, Sheen IJ, Lee PC, HuoTI, Su CW, Wang YJ, Chang FY, Lee SD. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepati 2003;10:277-84.

166.             Huang YH, Chen CH, Chang TT, Chen SC, Chiang JH, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Lee PC, HuoTI, Lee SD, Wu JC*. The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: A nationwide, multicentre study evaluated by cancer stage. Aliment Pharmacol Ther 2005;21:687-94.

167.             Huang YH, Wu JC*, Chen SC, Chen CH, Chiang JH, HuoTI, Lee PC, Chang FY, Lee SD. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter.Aliment Pharmacol Ther2006;23:129-35.

168.             Huang YH, Wu JC*, Chang TT, Sheen IJ, HuoTI, Lee PC, Su CW, Lee SD. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. J Viral Hepat 2006;13:336-42.

169.             Su CW, Huang YH, HuoTI, Shih HH, Sheen IJ, Chen SW, Lee PC, Lee SD, Wu JC*. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006;130:1625-35.

170.             Huang HC, Wu JC*, Huang YS, HuoTI, Lo JC, Li CP, Chang FY, Lee SD. Genetic distinctions and clinical characteristics of type 1 autoimmune hepatitis in Taiwan. Hepatogastroenterology 2008;55:605-8.

171.             Su CW, Hung HH, HuoTI, Huang YH, Li CP, Lin HC, Lee PC, Lee SD, Wu JC. Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: A follow-up study up to 18 years. Liver Int 2008;28:1305-13.

172.             Su CW, Wu JC,* Chiou YY, Tsay SH, HuoTI, Huang YH, Hung HH, Lin HC, Lee SD. Successful radiofrequency ablation therapy for hepatocellular carcinoma in a male patient with early- stage primary biliary cirrhosis and positive serum hepatitis B core antibody. J Chin Med Asso2008;71:40-4.

173.             Tang CP, ShiauYT, Huang YH, Tsay SH, HuoTI, Wu JC,* Lin HC, Lee SD.Cholestatic jaundice as the predominant presentation in a patient with autoimmune hepatitis.J Chin Med Assoc 2008;71:45-8.

174.             Huang YH*, Wu JC, Peng WL, HuoTI, Shih HH, Lan KH, Su CW, Lee SD. Generation of cytotoxicity against hepatitis Delta virus genotypes and quasispecies by epitope modification. J Hepatol 2009;50:779-88.

175.             Su CW, Chan CC, Hung HH,HuoTI,Huang YH, Li CP, Lin HC, Tsay SH,Lee PC,Lee SD, Wu JC*. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol 2009;42:876-83.

176.             Wu JC*, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, HuoTI, Sheen IS, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890-7.

177.             Hsu CY, Lee FY,HuoTI,Chan CY,Huang HC,Lin HC, Chang CC, Teng TH, Wang SS, Lee SD. Lack of therapeutic effects of gabexate mesilate on hepatic encephalopathy in rats withacute or chronic hepatic failure. J Gastroenterol Hepatol 2010;25:1325-8.

178.             Huang YH, Hung HH, Chan CC, Lai CR, Chu CJ, HuoTI, Lee PC, Su CW, Lan KH, Huang HC, Lee IC, Lin HC, Lee SD. Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads. Clin Vaccine Immunol 2010;17:1048-53.

179.             Lee IC, Huang YH, Chan CC,HuoTI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD.Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: A novel role of alpha-fetoprotein.Liver Int 2010;30:1161-8.

180.             Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, HuoTI, Lee PC, Kao WY, Lee SD, Wu JC. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis-B related hepatocellular carcinoma. Hepatol Int 2010;4:691-9.

181.             Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, Kao WY, HuoTI, Huang YS, Su YH, Lin HC, Lee SD, Wu JC. Survival rates are comparable following radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011;9:79-86.

182.             Kao WY, Chiou YY, Hung HH, Chou YH, Su CW, Wu JC, HuoTI, Huang YH, Lin HC, Lee SD. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: The clinical implication of aspartate aminotransferase-platelet ratio index. Eur J Gastroenterol Hepatol 2011;23:528-36.

183.             Lee IC, Huang YH, Chan CC, HuoTI, Chu CJ, Lai CR, Lee PC, Su CW, Wu JC, Lin HC, Lee SD. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin Nutr 2011;30:647-52.

184.             Lee JY, HuoTI, Huang HC, Lee FY, Lin HC, Chuang CL, Chang CC, Wang SS, Lee SD. Propranolol modulates the collateral vascular responsiveness to vasopressin via Gα-mediated pathway in portal hypertensive rats. Clin Sci 2011;121:545-54.

185.             Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, HuoTI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol 2012;46:62-70.

186.             Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Wu JC, HuoTI, Huang YH, Wu WC, Lin HC, Lee SD.Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy.Clin Radiol 2012;67:429-36.

187.             Hsu C, Yang TS, HuoTI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol 2012;56:1097-103.

188.             Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, Wu JC, HuoTI, Huang YH, Lee KC, Lin HC, Lee SD.Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation.J Clin Gastroenterol 2012;46:789-95.

189.             Hsieh YC, Chen CK, Su CW, Chan CC, HuoTI, Liu CJ, Fang WL, Lee KC, Lin HC. Outcome after percutaneous cholecystostomy for acute cholecystitis: A single-center experience. J Gastrointest Surg 2012;16:1860-8.

190.             Luo JC, HuoTI, Hou MC, Lin HY, Li CP, Lin HC, Chang FY, Lee FY. Clopidogrel delays gastric ulcer healing in rats. Eur J Pharmacol 2012;695;112-9.

191.             Chan CC, Cheng LY, Lu J, Huang YH, Chiou SH, Tsai PH, HuoTI, Lin HC, Lee FY. The role of interferon-γ inducible protein-10 in a mouse model of acute liver injury post induced pluripotent stem cells transplantation. PLoS One 2012;7:e50577.

192.             Chen PH, Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, HuoTI,, Huang YH, Wu WC, Chao Y, Lin HC, Wu JC. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Ann Hepatol 2013;12:263-73.

193.             Lee IC, Lin CH, Huang YH, HuoTI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One 2013;8:e58071.

194.             Yang YY, Lee FY, Hsu HC, Lee WS, Chuang CL, Chang CC, HuoTI, Huang YH, Huang CC, Huang CC.Validation of the behavior and concept based assessment of professionalism competence in postgraduate first-year residents.J Chin Med Assoc 2013;76:186-94.

195.             Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ,Hung HH, HuoTI, Wu JC. The influence of hepatitis B viral load and pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy. PLoS One 2013;8:e66457.

196.             Lee JY, HuoTI, Wang SS, Huang HC, Lee FY, Lin HC, Chuang CL, Lee SD.Diabetes diminishes the portal-systemic collateral vascular response to vasopressin via vasopressin receptor and Gα proteins regulations in cirrhotic rats.PLoS One 2013;8:e67703.

197.             Cheng YL, Wang YJ, Kao WY, Chen PH,HuoTI, Huang YH, Lan KH, Su CW, Chan WL, Lin HC, Lee FY, Wu JC. Inverse association between hepatitis B virus infection and fatty liver disease: A large-scale study in populations seeking for check-up. PLoS ONE 2013;8:e72049.

198.             Lee IC, Huang YH, Su CW, Wang YJ, HuoTI. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2atherapy: Apilot study. PLoS ONE 2013;8:e76798.

199.             Lee IC, Huang YH, Chau GY, HuoTI, Su CW, Wu JC, Lin HC. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer 2013;133:2895-902.

200.             Chiang CH, HuoTI, Sun CC, Hsieh JH, Chien Y, Lu KH, Lee SD. Induced pluripotent stem cells and hepatic differentiation. J Chin Med Assoc 2013;76:599-605.

201.             Chao J, HuoTI, Cheng HY, Tsai JC, Liao JW, Lee MS, Qin XM, Hsieh MT, Pao LH, Peng WH. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. PLoS One 2014;9:e96969.

202.             Hsu SJ, Wang SS, Hsin IF, Lee FY, Huang HC, HuoTI, Lee WS, Lin HC, Lee SD. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. Clin Sci 2014;126:633-44.

203.             Ho JK, Huo TI, Lin LC, Tsai TH. Pharmacokinetics of ractopamine and its organ distribution 1 in rats. J Agrc Food Chem 2014;62:9273-8.

204.             Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, HuoTI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine 2014;93:e348.

205.             Cheng YL, Wang YC, Lan KH, HuoTI, Huang YH, Su CW, Lin HC, Lee FY, Wu JC, Lee SD. Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Ann Hepatol 2015;14:181-9.

206.             Lee JY, HuoTI, Wang SS, Huang HC, Lee FY, Lin HC, Chuang CL, Lee SD.Diabetes enhances the intrahepatic vascular response to endothelin-1 in cirrhotic rats: association with the ETA receptor and pERK up-regulation. Liver Int 2015;35:704-12.

207.             Hsieh YC, Lee KC, Yang YY, HuoTI, Huang YH, Lin HC.Interleukin-1 receptor antagonist correlates with hepatic venous pressure gradient and predicts occurrence of overall complications and bacterial infections in patients with cirrhosis.Hepatol Res 2015;45:294-304.

208.             Yang BL, Wu WC, Fang KC, Wang YC, HuoTI, Huang YH, Yang HI, Su CW, Lin HC, Lee FY, Wu JC, Lee SD. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One 2015;10:e0120443.

209.             Tung HC, Lee FY, Wang SS, Tsai MH, Lee JY, HuoTI, Huang HC, Chuang CL, Lin HC, Lee SD.The beneficial effects of P2X7 antagonism in rats with bile duct ligation-induced cirrhosis.PLoS One 2015;10:e0124654.

210.             Lee IC, Chen YT, Chao Y, HuoTI, Li CP, Su CW, Lin HC, Lee FY, Huang YH.Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.Medicine 2015;94:e688.

211.             Chien Y, Chang YL, Li HY, Larsson M, Wu WW, Chien CS, Wang CY, Chu PY, Chen KH, Lo WL, Chiou SH, Lan YT, HuoTI, Lee SD, Huang PI.Synergetic effects of carboxymethyl-hexanoyl chitosan and cationic polyurethane-short branch PEI in miR122 gene delivery: Accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. Acta Biomater 2015;13:228-44.

212.             Chiang CH, Wu WW, Li HY, Chien Y, Sun CC, Peng CH, Lin AT, Huang CS, Lai YH, Chiou SH, Hung SI, Chang YL, Lan YT, Chien CS, HuoTI, Lee SD, Wang CY.Enhanced antioxidant capacity of dental pulp-derived iPSC-differentiated hepatocytes and liver regeneration by injectable HGF-releasing hydrogel in fulminant hepatic failure.Cell Transplant 2015;24:541-59

213.             Vitale A, HuoTI, CucchettiA, Lee YH, Volk M, Frigo AC, Cescon M, Tuci F, Pinna AD, Cillo U.The survival benefit of liver transplantation versus resection for hepatocellular carcinoma: impact of MELD score. Ann Surg Oncol 2015;22:1901-7.

214.             Hsu SJ, Wang SS, HuoTI, Lee FY, Huang HC, Chang CC, Hsin IF, Ho HL, Lin HC, Lee SD.The impacts of spironolactone on severity of portal-systemic collaterals and hepatic encephalopathy in cirrhotic rats.J Pharmacol Exp Ther 2015;355:117-24.

215.             Kao WY, Chao Y, Chang CC, Li CP, Su CW, HuoTI, Huang YH, Chang YJ, Lin HC, Wu JC.Prognosis of early-stage hepatocellular carcinoma: the clinical implications of substages of Barcelona Clinic Liver Cancer System based on a cohort of 1265 patients.Medicine 2015;94:e1929.

216.             Farinati F, Vitale A, Spolverato G, Pawlik TM, HuoTI, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group.Development and validation of a new prognostic system for patients with hepatocellular carcinoma.PLoS Med 2016;13:e1002006.

217.             Hsin IF, Lee JY, HuoTI, Lee FY, Huang HC, Hsu SJ, Wang SS, Ho HL, Lin HC, Lee SD. 2'-hydroxyflavanone ameliorates mesenteric angiogenesis and portal-systemic collaterals in rats with liver fibrosis.J Gastroenterol Hepatol 2016;31:1045-51.

218.             Luo JC, Peng YL, Chen TS, HuoTI, Hou MC, Huang HC, Lin HC, Lee FY. Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2.J Formos Med Assoc2016;115:764-72.

219.             Lee PC, Yeh CM, Hu YW, Chen CC, Liu CJ, Su CW, HuoTI, Huang YH, Chao Y, Chen TJ, Lin HC, Wu JC. Antiplatelet therapy is associated with a better prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. Ann Surg Oncol2016;23(Suppl 5):874-883.

220.             Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, HuoTI, Lin HC, Huang YH. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep 2016;6:29605.

221.             Tung HC, Hsu SJ, Tsai MH, Lin TY, Hsin IF, HuoTI, Lee FY, Huang HC, Ho HL, Lin HC, Lee SD. Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats. Clin Sci 2017;131:69-86. 

222.             Fang KC, Su CW, Chiou YY, Lee PC, Chiu NC, Liu CA, Chen PH, Kao WY, Huang YH, HuoTI, Hou MC, Lin HC, Wu JC. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. Eur Radiol 2017;27:2600-2609.

223.             Hsieh WY, Chen PH, Lin IY, Su CW, Chao Y, HuoTI, Huang YH, Hou MC, Lin HC, Wu JC. The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Sci Rep 2017;7:42577.

224.             Fang KC, Cheng YL, Su CW, Wang YJ, Lan KH, HuoTI, Huang YH, Chu CJ, Lin CC, Hou MC, Lin HC, Lee FY, Wu JC, Lee SD. Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. J Chin Med Assoc 2017;80:125-132.

225.             Cheng YL, Wang YJ, Lan KH, HuoTI, Huang YH, Su CW, Hsieh WY, Hou MC, Lin HC, Lee FY, Wu JC, Lee SD.Fattyliver index and lipid accumulation product can predict metabolic syndrome in subjects without fatty liver disease.Gastroenterol Res Pract 2017;2017:9279836.

226.             Gavriilidis P, Roberts KJ, Askari A, Sutcliffe RP, Huo TI, Liu PH, Hidalgo E, Compagnon P, Lim C, Azoulay D. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. J Hepatol 2017;67:991-998.

227.             Ho HL, HuoTI, Chang T, Lee WS, Hsin IF, Lee FY, Huang HC, Hou MC, Lee SD.Ascorbate lacks significant influence in rats with bile duct ligation-induced liver injury.J Chin Med Assoc 2017;80:539-550.

228.             Kao WY, Su CW, Chiou YY, Chiu NC, Liu CA, Fang KC, HuoTI, Huang YH, Chang CC, Hou MC, Lin HC, Wu JC. Hepatocellular carcinoma: Nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation. Radiology 2017;285:670-680.

229.             Jiang SH, Cheng YY, HuoTI, Tsai TH. Pharmacokinetics of rhodamine 110 and its organ distribution in rats. J Agr Food Chem2017;65:7797-7804.

230.             Lee IC, Chau GY, Yeh YC, Chao Y, HuoTI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure.PLoS One 2017;12:e0188552.

231.             Lee PC, Chen YT, Chao Y, HuoTI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH. Validation of the ALBI grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. Liver Int 2018;38:321-330.

 

 

藥理所首頁